Current News

Print version | PDF version | Send article | RSS feed

Predictive genetic test for bowel cancer treatment is introduced in the UK
Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test

20 Mar 2008 - Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for advanced bowel cancer Vectibix(r) (panitumumab). It is the first time that the European Commission has licensed a bowel cancer product with the stipulation that a predictive test should be carried out. The Lab 21 test was developed by DxS Ltd, a developer of biomarker assays and companion diagnostics for targeted cancer therapies.
 
Introduced to the UK earlier this year, Vectibix is currently licensed for patients with metastatic bowel cancer for whom standard chemotherapy has failed in patients with a specific gene mutation. In a biomarker analysis of the pivotal clinical trial, the drug doubled median progression-free survival in patients with non-mutated (wild type) KRAS (Kirsten Rat Sarcoma 2 viral oncogene homologue) compared with patients receiving best supportive care alone.
 
Amgen scientists had discovered that only those patients with the non-mutated (wild type) KRAS would respond to Vectibix. Patients with metastatic bowel cancer will be tested for the presence of the wild type KRAS gene before they are prescribed the drug. Approximately 60 per cent of patients with advanced bowel cancer have wild type KRAS. Of these, up to 60 per cent would be expected to respond to Vectibix.